Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.62 |
| ▸ | GALR3 | O60755 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | HTT | P42858 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977976 | 0.86 | SMN1; SMN2 (0.59) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 | |
| SCHEMBL15347754 | 0.84 | LMNA (0.65) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 | |
| SCHEMBL8506287 | 0.78 | HTT (0.59) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 | |
| SCHEMBL1520577 | 0.77 | LMNA (0.75) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 | |
| SCHEMBL29898477 | 0.77 | LMNA (0.75) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 | |
| SCHEMBL29386010 | 0.77 | EGFR (1.00) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 | |
| SCHEMBL7612718 | 0.77 | EGFR (1.00) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 | |
| SCHEMBL29898476 | 0.77 | LMNA (0.75) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 | |
| SCHEMBL10061697 | 0.76 | SMN1; SMN2 (0.67) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 | |
| SCHEMBL8498702 | 0.76 | SMN1; SMN2 (0.60) | EGFRRAB9ANR2F2GALR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569925-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-08-03 | — | — | US | disclosed |
| US-7074799-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040156869-A1 | 2-substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR88 | EGFR 833/4885RAB9A 923/4885NR2F2 1040/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | EGFR 3060/4885RAB9A 4200/4885NR2F2 1157/4885 |
| US-20040156869-A1 | 2-substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | EGFR 839/4885RAB9A 1012/4885NR2F2 834/4885 |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | EGFR 833/4885RAB9A 923/4885NR2F2 1040/4885 |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | EGFR 776/4885RAB9A 938/4885NR2F2 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.